At week @ , @ ( @ % ) patients receiving dolutegravir and @ ( @ % ) patients receiving darunavir plus ritonavir had HIV-@ RNA of less than @ copies per mL ( adjusted difference @ % , @ % CI @-@ ) , non-inferiority and on pre-specified secondary analysis dolutegravir was superior ( p = @ ) .